Pairing obinutuzumab with venetoclax in relapsed CLL

Leuk Lymphoma. 2024 May;65(5):543-545. doi: 10.1080/10428194.2024.2323682. Epub 2024 Mar 18.

Authors

Kerry A Rogers¹, Philip A Thompson^{2

3}

Affiliations

¹ Division of Hematology, The Ohio State University, Columbus, OH.
² Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.
³ The Sir Peter MacCallum Department of Clinical Oncology, University of Melbourne, Parkville, Australia.

PMID: 38497550
DOI: 10.1080/10428194.2024.2323682

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / pathology
Recurrence
Sulfonamides* / administration & dosage
Sulfonamides* / therapeutic use
Treatment Outcome

Substances

Bridged Bicyclo Compounds, Heterocyclic
venetoclax
obinutuzumab
Antibodies, Monoclonal, Humanized
Sulfonamides